Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)

Next Previous
Search
Trial Profile

A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Omalizumab; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms OSMO
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 16 Mar 2020 Results (n=145) of a post-hoc analysis assessing clinical outcomes after switching stratified by baseline asthma control and health related quality of life quartiles were publised at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 16 Mar 2020 Results of post-hoc analysis of changes in clinical outcomes after switching stratified by exacerbation history in the prior year and maintenance oral corticosteroid (OCS) use, published at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 02 May 2019 Results published in the Allergy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top